GL1X · GenesisL1 explorer

Research workbench

Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4- fluoro-1H-pyrazol-1-YL)ETHOXY]-6-methylphenyl}-N-(2,2- difluoropropyl)-5,7-dihydro-6H-PYRROLO[3,4-D]PYRIMIDINE-6-carboxamide

Analyse Optimization of potent, selective, and orally bioavailable… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3R4O
Type
protein
Length
420 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Heat shock protein HSP 90-alpha
UniProt
P07900
Ligands
FU3
Pockets
4 · best druggability 0.75

Structure

x-ray diffraction · 1 distinct chain · 42% helix, 25% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BHeat shock protein HSP 90-alphaprotein21042% helix, 25% strandP07900

Ligands and binding sites

  • FU3 · 2-amino-N-cyclobutyl-4-[2,4-dichloro-6-(4,4,4-trifluorobutoxy)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17970.750.8069empty
22540.630.8127FU3
32460.620.8131FU3
41050.340.7320empty

Interfaces

1 interface between chains.

  • A–B · 1104 Ų buried · 15 hydrogen bonds · protein-protein

Compared structures

  • 3R4O · Optimization of Potent, Selective, and Orally Bioavailable… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.